Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ebos GroupASX:EBO +0.97%80 Receivables Turnover is 4.48 as of Dec. 2025. GuruFocus rates ASX:EBO with a GF Score™ of 80/100 and a GF Value™ of A$31.55 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 116 Medical Distribution companies, Ebos Group ranks better than 82.76% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Ebos Group's Revenue for the
six
months ended in Dec. 2025 was A$6,828 Mil. Ebos Group's average Accounts Receivable for the
six
months ended in Dec. 2025 was A$1,524 Mil.
Hence, Ebos Group's Receivables Turnover for the
six
months ended in Dec. 2025 was 4.48.
Ebos Group (ASX:EBO) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Ebos Group Receivables Turnover Related Terms
Ebos Group Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Ebos Group's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:EBO vs MCK, CAH, COR: Receivables Turnover Comparison
For the Medical Distribution subindustry, Ebos Group's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ebos Group Receivables Turnover vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Ebos Group's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Ebos Group's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ebos Group (ASX:EBO) has a Receivables Turnover of 4.48 as of Dec. 2025. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ebos Group and its competitors. According to the industry distribution chart, Ebos Group ranks #20 out of 116 companies in the Medical Distribution industry, placing it in the top 17.2%.
Is Ebos Group's Receivables Turnover too high?
Ebos Group's current Receivables Turnover is 4.48. The Medical Distribution industry median Receivables Turnover is 4.55. Ebos Group's value of 4.48 is 1.4% below this industry median. Based on the distribution chart, Ebos Group ranks #20 out of 116 companies in the Medical Distribution industry, which is in the top quartile — a strong position relative to peers. Overall, Ebos Group has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Ebos Group's Receivables Turnover compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Ebos Group ranks #20 out of 116 companies for Receivables Turnover. This places Ebos Group in the top 17% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 4.55. Ebos Group's value of 4.48 is 1.4% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Medical Distribution company?
The median Receivables Turnover among Medical Distribution companies is 4.55, based on 116 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ebos Group's current Receivables Turnover of 4.48 is 1.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Ebos Group and its competitors. For the Medical Distribution industry, the median Receivables Turnover is 4.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ebos Group's current Receivables Turnover is 4.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ebos Group stock overvalued right now?
Based on GuruFocus' analysis, Ebos Group (ASX:EBO) is currently considered Significantly Undervalued. The stock's GF Value™ is A$31.55, compared to a current price of A$18.80 — trading 40.4% below its estimated fair value. The current Receivables Turnover is 4.48 and 1.4% below the Medical Distribution industry median of 4.55. Ebos Group's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Ebos Group (ASX:EBO), the current Receivables Turnover is 4.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ebos Group (ASX:EBO) Overvalued in 2026?
Based on GuruFocus' analysis, Ebos Group stock appears to be undervalued.
The current stock price of A$18.80 is trading 40.4% below its estimated GF Value™ of A$31.55.
GuruFocus considers Ebos Group to be Significantly Undervalued.
Key valuation signals for ASX:EBO:
Receivables Turnover: 4.48
GF Value™: A$31.55 vs. price of A$18.80 (40.4% below fair value)
Industry Position: 1.4% below the Medical Distribution median (#20 of 116)
No single metric tells the full story. See the ASX:EBO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ebos is the largest pharmaceutical wholesaler across Australia and New Zealand. It services community pharmacies and hospitals, which contribute around 50% and 30% of revenue, respectively. Drug pricing and wholesale margins for PBS medicine are governed by the Australian government's Pharmaceutical Benefits Scheme, or PBS. Wholesale gross margins are capped at 7% for community pharmacy and 10% for hospitals, and ongoing price reform typically results in low-single-digit revenue growth. Aside from pharma distribution, Ebos operates an animal health product wholesale, manufacturing and retail business, as well as undertaking third party logistics services. These segments are smaller contributors to group revenue but due to the unregulated nature are higher-margin operations.
80GF Score
Get the complete analysis for ASX:EBO
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EBO has been successfully added to your 
